BioNTech (ADR)
Develops oncology medicines while commercializing the Pfizer-partnered Comirnaty vaccine.
Something off on this page? Send us feedback.
Profile
Markets Pfizer-partnered Comirnaty, its only commercial medicine, while developing oncology candidates across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies. Revenue remains tied to COVID-19 vaccine demand, and expansion beyond it depends on clinical results, regulatory approvals, collaborators and commercialization.
Markets Comirnaty, the Pfizer-partnered COVID-19 vaccine and its only approved commercial medicine, while developing cancer treatments across immunomodulators, antibody-drug conjugates and mRNA immunotherapies. Based in Mainz, the commercial business is anchored in a global collaboration, while oncology candidates remain investigational.
Capabilities span immunology, computational design and manufacturing, built from an oncology-focused research base and expanded through acquisitions. The same mRNA platform that supported Project Lightspeed now sits within a broader multi-platform development portfolio.
Revenue remains heavily dependent on declining COVID-19 vaccine demand. Expansion beyond that product depends on clinical outcomes, regulatory approvals, collaborator execution, manufacturing capacity and successful commercialization, while a founder-management transition and manufacturing consolidation are underway.
Company facts
Key statistics
Year to date +5.6% · Average volume (30d) 1.5M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | Canaccord Genuity | Target | $158 | $142 | ||
| Jul 8, 2026 | Morgan Stanley | Reiterate | Overweight | $126 | $119 | |
| May 27, 2026 | UBS | Upgrade | Neutral | Buy | $168 | $135 |
| May 21, 2026 | Bernstein | Target | $96 | |||
| May 6, 2026 | Canaccord Genuity | Reiterate | Buy | $171 | $158 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | −$2.40 | −$3.70 | −54.3% | $180.2M | $120.6M | −33.1% | −0.98% |
| May 5, 2026Q1 FY26 | −$2.52 | −$2.28 | +9.5% | $207.4M | $136.4M | −34.2% | −0.25% |
| Mar 10, 2026Q4 FY25 | −$0.22 | −$0.38 | −72.7% | $902.3M | $1.07B | +18.1% | +8.28% |
| Nov 3, 2025Q3 FY25 | −$1.12 | −$0.14 | +87.5% | $843.7M | $1.78B | +110.9% | +0.84% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $211.8M | $302.2M | $1.76B | $1.04B | $139.1M | $122.4M | |
| Gross profit | $114.7M | $213.7M | $1.59B | $659.0M | −$87.9M | $10.0M | |
| Operating income | −$618.8M | −$580.6M | −$54.3M | −$267.2M | −$778.6M | −$1.10B | |
| Net income | −$481.8M | −$447.9M | −$33.3M | −$350.1M | −$626.4M | −$951.0M | |
| Diluted EPS | −$2.00 | −$1.85 | −$0.14 | −$1.43 | −$2.48 | −$3.75 | |
| Gross margin | 54.2% | 70.7% | 90.2% | 63.3% | -63.2% | 8.1% | |
| Operating margin | -292.2% | -192.1% | -3.1% | -25.7% | -559.8% | -897.8% |
Fiscal years (4-quarter sums)FY21 $21.99B · FY22 $20.06B · FY23 $4.42B · FY24 $3.19B · FY25 $3.32B
Revenue by product · FY25
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $11.28B · Total debt $366.1M · Total assets $23.56B · Shareholders' equity $20.57B
Dividends
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 2, 2022 | Jun 3 | Jun 17 | $2.111 |
Ownership
Shares outstanding 251.20M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Athos KG | 101.70M | 40.20% | 13G | May 14, 2026 |
| Ugur Sahin | 40.08M | 15.80% | 13G | May 15, 2026 |
| FMR LLC | 7.57M | 3.01% | 13F | Aug 13, 2026 |
| Primecap Management Co/CA/ | 3.77M | 1.50% | 13F | Aug 14, 2026 |
| Dodge & Cox | 3.68M | 1.46% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 22, 2026 | Sierk Poetting | officer: Chief Operating Officer | −50,000 | $110.56 |
Peers
- Moderna
mRNA rival across seasonal COVID-19 vaccines and cancer immunotherapy
- Merck
Checkpoint and mRNA-oncology rival across solid tumors
- AstraZeneca (ADR)
Competes in HER2 ADCs and checkpoint therapy across solid tumors
- Summit Therapeutics
Direct PD-1×VEGF bispecific rival in lung and colorectal cancer
- Novavax
Protein-based alternative in seasonal COVID-19 vaccination
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioNTech (ADR) | $102.50 | +0.40% | $25.64B | — | — | 8.4 | −60.7% |
| Moderna | $136.53 | −1.06% | $54.75B | — | — | 24.6 | +2.1% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Summit Therapeutics | $13.71 | +0.03% | $10.95B | — | — | — | — |
| Novavax | $9.27 | +0.11% | $1.52B | — | — | 3.7 | −76.3% |
| Median | 71.6 | 16.2 | 4.8 | +3.6% |